Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPHACAINE vs BUPIVACAINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.
Bupivacaine hydrochloride is an amide-type local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby inhibiting the generation and propagation of action potentials and producing reversible local anesthesia.
Local anesthesia for dental procedures,Local anesthesia for minor surgical procedures,Epidural anesthesia (off-label),Peripheral nerve blocks (off-label)
Local or regional anesthesia for surgical procedures,Dental anesthesia,Obstetric anesthesia (epidural),Postoperative pain management,Off-label: peripheral nerve blocks, sympathetic nerve blocks
10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.
0.25% to 0.5% solution infiltrated locally, up to 175 mg (without epinephrine) or 225 mg (with epinephrine 1:200,000) per dose; maximum 400 mg per 24 hours. For epidural: 0.5% to 0.75% solution, 15-20 m L for surgical anesthesia.
Terminal elimination half-life: 3.5-5.0 hours (prolonged in hepatic impairment; requires dose adjustment in Child-Pugh B or C).
Terminal elimination half-life: 2.7 hours (adults); prolonged in neonates (8.1 hours) and patients with hepatic impairment; clinical context: half-life increases with repeated dosing due to accumulation.
ALPHACAINE is metabolized primarily by the liver via cytochrome P450 enzymes, specifically CYP3A4 and CYP1A2, to inactive metabolites that are excreted renally.
Primarily hepatic via conjugation with glucuronic acid; CYP3A4 and CYP1A2 involved in metabolism to pipecoloxylidine and desbutylbupivacaine.
Renal: ~60-70% unchanged; Hepatic metabolism: ~20-30% via CYP3A4 and CYP2C9; Fecal: <10%.
Primarily hepatic metabolism (CYP3A4, CYP1A2, and amidases) to pipecoloxylidine and desbutylbupivacaine; less than 5% excreted unchanged in urine; negligible biliary/fecal excretion.
~92-95% bound, primarily to albumin and alpha-1-acid glycoprotein.
Approximately 95% bound to alpha-1-acid glycoprotein (AAG) and albumin; binding is concentration-dependent and decreases in acidosis.
Vd: 2.5-4.0 L/kg (indicates extensive tissue distribution; large Vd suggests accumulation in peripheral tissues).
Vd: 0.73 L/kg (range 0.5-1.0 L/kg) in adults; reflects extensive tissue binding; lower in neonates (0.3-0.6 L/kg) due to reduced adipose tissue.
Oral: 65-80% (first-pass effect); IM: 90-100%; IV: 100%.
Not applicable for intravenous use; epidural: ~100% (systemic absorption from epidural space); peripheral nerve block: variable (systemic absorption depends on site and dose); oral: negligible (<5%) due to extensive first-pass metabolism.
GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use.
No specific dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: use with caution, reduce dose by 25% and monitor for toxicity. For GFR <10 m L/min: avoid or reduce dose by 50% with close monitoring.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25-50%. Child-Pugh C: contraindicated or use minimal effective dose with extreme caution.
0.5-1 mg/kg IM or IV every 4-6 hours; maximum 4 mg/kg/day.
Infants and children: 0.25-0.5% solution, maximum 2 mg/kg (without epinephrine) or 3 mg/kg (with epinephrine), not to exceed 175 mg total.
Initiate at 50% of adult dose; titrate cautiously due to increased sensitivity and risk of adverse effects.
Elderly patients: reduce dose by 25-50% due to decreased clearance and increased sensitivity; consider lower concentrations and volumes; avoid rapid infusion.
There is no FDA black box warning for ALPHACAINE.
Risk of cardiac arrest and death following unintended intravenous injection or administration of high doses; resuscitation may be difficult and prolonged.
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Use with caution in patients with cardiovascular disease,May cause methemoglobinemia in rare cases,Avoid use in patients with known hypersensitivity to amide-type anesthetics
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Avoid for spinal anesthesia when high doses are needed due to neurotoxicity risk,Monitor for signs of CNS and cardiovascular toxicity,Use in pregnant women only if clearly needed (Category C)
Hypersensitivity to ALPHACAINE or any component of the formulation,Severe hepatic impairment,Severe uncontrolled hypotension,Injection into infected or inflamed areas,History of malignant hyperthermia (relative contraindication)
Hypersensitivity to bupivacaine or other amide anesthetics,Severe hypotension (e.g., hypovolemic shock),Inflammation or sepsis at injection site,Paracervical block in obstetrics (associated with fetal bradycardia),Use for intravenous regional anesthesia (Bier block)
No clinically significant food interactions. Grapefruit juice does not affect clearance. Avoid excessive alcohol intake as it may increase risk of sedation and dizziness.
No known food interactions. Grapefruit juice may affect hepatic metabolism via CYP3A4 inhibition, but clinical significance is minimal. Maintain normal diet.
FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and third trimesters: Potential for fetal growth restriction, preterm labor, and neurobehavioral alterations. Avoid use unless benefit outweighs risk.
Bupivacaine is classified as FDA Pregnancy Category C. In first trimester, no well-controlled studies; animal studies have shown potential for fetal toxicity at high doses. Second and third trimesters: risk of fetal bradycardia and acidosis due to placental transfer. Epidural use may cause maternal hypotension reducing uteroplacental perfusion. Avoid paracervical block in pregnancy due to risk of fetal bradycardia.
Excreted in human milk; M/P ratio estimated at 0.95. Peak milk concentration occurs 1-2 hours after maternal dose. Limited data suggest low risk to term infants, but caution in preterm or ill infants. American Academy of Pediatrics recommends avoiding breastfeeding within 4 hours of maternal dose.
Bupivacaine is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.30. It is considered compatible with breastfeeding; however, monitor infant for signs of local anesthetic toxicity such as drowsiness or irritability.
Increased volume of distribution and enhanced hepatic clearance (CYP3A4 induction) in pregnancy require 30-50% dose escalation. Monitor trough levels to achieve therapeutic range (5-15 mg/L). Postpartum dose should be reduced to pre-pregnancy levels within 72 hours.
Increased plasma volume and decreased plasma protein binding in pregnancy may require reduced doses to avoid toxicity. However, standard epidural doses often remain similar; dose adjustment should be based on clinical response and weight. Use lower doses for combined spinal-epidural. Maximum single epidural dose: 2.5 mg/kg (non-pregnant), but in pregnancy consider 2.0 mg/kg due to increased sensitivity.
ALPHACAINE (liposomal bupivacaine) provides extended analgesia up to 72 hours. Do not use with bupivacaine HCl or other local anesthetics as it may disrupt liposomal formulation. Avoid bolus injection; administer by slow infiltration only. Use with caution in hepatic impairment due to decreased clearance. Maximum dose: 266 mg (20 m L of 1.3% solution) in adults.
Bupivacaine is a long-acting amide local anesthetic. Maximum single dose is 2.5 mg/kg (with epinephrine 3 mg/kg). Cardiotoxicity is greater than lidocaine; avoid intravascular injection. Use with caution in hepatic impairment. For labor analgesia, 0.0625-0.125% with fentanyl is common. Adding epinephrine prolongs duration and reduces peak plasma concentration.
You will receive a long-acting local anesthetic that provides pain relief for up to 3 days after surgery.,Do not apply heat or ice packs directly over the injection site for 24 hours.,Report any signs of infection such as redness, swelling, or warmth at the injection site.,Avoid driving or operating machinery for 24 hours if you feel dizzy or drowsy.,Take over-the-counter pain relievers as directed if breakthrough pain occurs.
Report any numbness or tingling beyond expected area of anesthesia.,Seek immediate medical attention if you experience ringing in ears, metallic taste, dizziness, or seizures.,Inform your healthcare provider if you have liver disease or are taking antiarrhythmics.,Avoid driving or operating machinery until full sensation returns.,Do not apply heat or cold to the numb area to prevent burns or frostbite.
No interactions on record
"The concurrent administration of nitrous oxide and bupivacaine may increase the risk of cardiovascular depression and arrhythmias due to synergistic cardiovascular depressant effects. Nitrous oxide can cause sympathetic nervous system activation and myocardial depression, while bupivacaine prolongs ventricular depolarization and increases the risk of reentrant arrhythmias, particularly at high doses. This combination may lead to hypotension, bradycardia, or more severe cardiac conduction abnormalities, especially in patients with preexisting cardiac disease."
"The coadministration of bupivacaine, a sodium channel blocker used for local anesthesia, with diclofenamide, a carbonic anhydrase inhibitor and diuretic, may lead to metabolic acidosis and altered electrolyte balance, thereby increasing the risk of bupivacaine-induced cardiotoxicity and central nervous system (CNS) toxicity. Diclofenamide can cause hypokalemia and hypocalcemia, which potentiate the sodium channel blocking effects of bupivacaine, resulting in arrhythmias, seizures, or other adverse effects. This interaction is clinically significant especially in patients with renal impairment or those on multiple electrolyte-altering medications."
"Oxymorphone, a potent mu-opioid receptor agonist, and bupivacaine, a local anesthetic that blocks sodium channels, both depress the central nervous system (CNS) and respiratory drive. Coadministration may lead to additive CNS and respiratory depression, increasing the risk of severe adverse effects such as hypotension, bradycardia, and respiratory arrest. Clinical outcomes include enhanced sedation, confusion, and possibly fatal respiratory compromise, especially in patients with compromised cardiovascular function or those receiving high doses of either agent."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALPHACAINE vs BUPIVACAINE HYDROCHLORIDE, answered by our medical review team.
ALPHACAINE is a Local Anesthetic that works by ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.. BUPIVACAINE HYDROCHLORIDE is a Local Anesthetic that works by Bupivacaine hydrochloride is an amide-type local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby inhibiting the generation and propagation of action potentials and producing reversible local anesthesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPHACAINE and BUPIVACAINE HYDROCHLORIDE depend on the specific clinical indication. These are both Local Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPHACAINE is: 10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.. The standard adult dose of BUPIVACAINE HYDROCHLORIDE is: 0.25% to 0.5% solution infiltrated locally, up to 175 mg (without epinephrine) or 225 mg (with epinephrine 1:200,000) per dose; maximum 400 mg per 24 hours. For epidural: 0.5% to 0.75% solution, 15-20 m L for surgical anesthesia.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALPHACAINE and BUPIVACAINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALPHACAINE is classified as Category C. FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and th. BUPIVACAINE HYDROCHLORIDE is classified as Category C. Bupivacaine is classified as FDA Pregnancy Category C. In first trimester, no well-controlled studies; animal studies have shown potential for fetal toxicity at high doses. Second . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.